Cancer News: Kidney
Sunitinib increases disease-free survival in renal cell carcinoma
Sunitinib can increase disease-free survival as adjuvant treatment for renal cell carcinoma after nephrectomy.
Surgery with targeted therapy benefits metastatic renal cancer patients
Cytoreductive surgery with targeted therapy improves survival rates in metastatic renal cell cancer patients.
Everolimus and bevacizumab against non-clear cell renal carcinoma
Patients with advanced non-clear cell renal cell carcinoma (ncRCC) benefited from the combination treatment of everolimus and bevacizumab, researchers report.
Active surveillance in advanced kidney cancer. Is it possible?
A study reveals that some adult advanced kidney cancer patients may safely opt for an active surveillance scheme instead of aggressive treatments.
EU regulator backs lenvatinib and everolimus for kidney cancer
Lenvatinib combined with everolimus received a positive opinion by the EU regulator for the treatment of adult patients with advanced renal cell carcinoma.
Metastatic kidney cancer patients lived longer after surgery
Removing with surgery a cancerous kidney helped metastatic kidney cancer patients live longer, a new study reveals.
Advanced kidney cancer patients lived longer with nivolumab
Advanced kidney cancer patients treated after disease progression with immunotherapy nivolumab survived longer, a new phase 3 study shows.
US regulators approve lenvatinib and everolimus for kidney cancer
The combination of lenvatinib and everolimus received FDA approval for the treatment of advanced renal cell carcinoma following prior anti-angiogenetic therapy.
Nivolumab gets EU approval for lung and kidney cancers
EU regulators have approved nivolumab as a treatment against advanced or metastatic non-squamous non-small cell lung cancer and advanced renal cell carcinoma.
Cabozantinib shows promise to advanced kidney cancer
A new study comparing the current standard care for renal cell carcinoma, everolimus and cabozantinib reveals the increased benefit of cabozantinib.
FDA approved immunotherapy drug Opdivo to treat kidney cancer
U.S. regulators approved Bristol-Myers Squibb's immunotherapy drug Opdivo for the treatment of patients with advanced (metastatic) renal cell carcinoma.
Combo treatment promising for metastatic renal cell carcinoma
Patients of renal cell carcinoma benefited significantly when treated with a combination of lenvatinib with everolimus, a new phase 2 study reveals.
Nivolumab brings hope to patients with advanced kidney cancer
The targeted drug nivolumab extended survival in patients with advanced kidney cancer whose disease has progressed on prior treatment, according to a new study.
Immunotherapy drug Opdivo improved survival in kidney cancer
The immunotherapy drug Opdivo extended survival rates in kidney cancer patients by more than two years, a new study reports.
Good news for patients with metastatic renal cell carcinoma
The results of two phase 3 clinical trials on metastatic renal cell carcinoma showed that patients benefited from two immunotherapeutic agents, nivolumab and cabozantinib.
Combination therapy extended survival in kidney cancer patients
Renal cell carcinoma patients treated with the combined therapy of lenvatinib with everolimus survived longer without disease progression, a new study reveals.
Gastrointestinal tumors associated with higher cancer risk
Patients with gastrointestinal stromal tumors may develop additional malignancies before and after their diagnosis, according to the first population-based study.
Kidney cancer: identical results for common treatment and placebo
Clinical findings indicate that widely used treatments of metastatic kidney cancer, sorafenib and sunitinib, had similar disease recurrence results with placebo.
Some childhood cancer survivors may face subsequent renal problems
Adult survivors of childhood cancers who underwent certain chemotherapy treatments or kidney surgery had worse kidney function that did not recover over time. Because of this, they may be at higher risk for premature renal failure, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Scientists identify genetic errors in 12 major cancer types
Examining 12 major types of cancer, scientists at Washington University School of Medicine in St. Louis have identified 127 repeatedly mutated genes that appear to drive the development and progression of a range of tumors in the body. The discovery sets the stage for devising new diagnostic tools and more personalized cancer treatments.
Prognostic factors could aid RCC metastasectomy decisions
Researchers have identified four factors that are associated with survival time in patients who undergo metastasectomy for metastatic renal cell carcinoma (mRCC).
Stage and grade dominate RCC outcomes
Tumor grade and stage have emerged as the most important predictors of mortality in a competing risks analysis of patients undergoing nephrectomy for renal cell carcinoma (RCC).
A variety of cancers destroyed by drug combination therapy
Results from a recent preclinical study have shown that a new drug combination therapy being developed effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells. The results lay the foundation for researchers to plan a future phase 1 clinical trial to test the safety of the therapy in a small group of patients.
Targeted therapy efficacy in metastatic Renal Cell Carcinoma (RCC) predicted by early tumor shrinkage
Metastatic renal cell carcinoma (mRCC) tumor shrinkage after targeted therapy may prolong long-term survival for this type of kidney cancer, research shows.
Kidney cancer patients treated with robot-assisted partial nephrectomy preserve kidney function
Patients treated for kidney cancer with robot-assisted partial nephrectomy & have chronic kidney disease preserved kidney function, even better than those without chronic kidney disease.
Kidney cancer advances require emphasis on molecular biology and genetics
Renal cell carcinoma (RCC) advances require more emphasis on molecular biology and genetics, according to a researcher at the Genitourinary Cancers Symposium.
Partial nephrectomy is better for some kidney cancer patients
Younger renal cancer patients with localized disease may benefit more from partial nephrectomy compared with complete removal of the kidney, researchers found.
Clinical benefit for advanced kidney cancer immunotherapy confirmed
A study found that patients with metastatic kidney cancer can tolerate and benefit from a treatment called high-dose interleukin-2 (HDIL-2) immunotherapy.
Kidney cancer control procedures estimated to have similar benefit
A large study showed that for kidney cancer patients, surgery and less radical, needle-guided procedures offer near equivalent cancer control for small tumors.